Mylan Inc (NASDAQ:MYL), the biggest U.S. generic-drug maker, was rejected in a second bid to buy Meda AB (MEDAA), the Swedish producer of the Dymista allergy medicine. Meda stock fell the most in almost three years. All contact between Meda and Mylan has been terminated, the Solna, Sweden-based company said in a statement, without specifying financial details. The Canonsburg, Pennsylvania-based suitor raised its offer to about 43.8 billion kronor ($6.7 billion) from an earlier, undisclosed figure, people with knowledge of the matter said last week.Mylan Inc (NASDAQ:MYL) shares after opening at $49.86 moved to $53.57 on last trade day and at the end of the day closed at $52.10. Company price to sales ratio in past twelve months was calculated as 2.80 and price to cash ratio as 66.52. Mylan Inc (NASDAQ:MYL) showed a positive weekly performance of 11.04%.
Ironwood Pharmaceuticals (NASDAQ:IRWD) will release its earnings data on Tuesday, April 29th.Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares fell -11.07% in last trading session and ended the day on $10.68. IRWD return on equity ratio is recorded as -340.70% and its return on assets is -83.10%. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) yearly performance is -29.97%.
Karyopharm Therapeutics Inc (NASDAQ:KPTI) a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with advanced gynecologic malignancies including cervical, ovarian and uterine carcinomas. The study, referred to as the SIGN Study, is being led by Ignace Vergote, MD, at the University Hospitals, Leuven, Belgium. SIGN is also open at Rigshospitalet in Copenhagen, Aalborg University Hospital, Aalborg, and Herlev Hospital, Herlev, all in Denmark. Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares moved down -7.00% in last trading session and was closed at $25.63, while trading in range of $25.45-28.33. Karyopharm Therapeutics Inc (NASDAQ:KPTI) year to date performance is 11.82%.
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) a specialty pharmaceutical company, has received a patent from US Patent and Trademark Office, or USPTO, for the treatment of heat stroke with the company’s dantrolene sodium for injectable suspension. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) weekly performance is -15.10%. On last trading day company shares ended up $10.23. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) distance from 50-day simple moving average is -22.18%. Analysts mean target price for the company is $21.67.